Literature DB >> 30794893

Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma.

Sara N Meyer1, José A Galván1, Stefan Zahnd1, Lena Sokol2, Heather Dawson1, Alessandro Lugli1, Inti Zlobec3.   

Abstract

Tumor buds in colorectal cancer are hypothesized to undergo a (partial) epithelial-mesenchymal transition (EMT). If so, cytokeratin (CK) and vimentin (VIM) co-expression is expected. CK+/VIM+ can also be found in some stromal cells; however, their origin remains unclear. Here, we determine the frequency of CK+/VIM+ tumor cells and characterize the CK+/VIM+ stroma in colorectal cancer. Three cell populations (CK+, VIM+, CK+/VIM+) were sorted using DepArray and fluorescence-activated cell sorting (FACS). Tumor areas were selected to include tumor center, stroma and tumor budding. Fluorescence microscopy was used to visualize co-expressing cells on whole slides. A next-generation tissue microarray (ngTMA) of matched Pan-CK-positive and -negative stroma was constructed and stained for E-cadherin, VIM, Snail1, Twist1, Zeb1 and Zeb2, COL11A1, SPARC, CD90, α-SMA, FAP and WT1. CK+/VIM+ co-expressing tumor cells were detected using all three methods. With DepArray, only tumor budding areas contained CK+/VIM+ cells. The proportion of CK+/VIM+ tumor cells was low (1.5%-22%). CK+ stroma was associated with aggressive tumor features like distant metastasis (P = .0003), lymphatic invasion (P = .0009) and tumor budding (P = .0084). CK+/VIM+ stroma was characterized by positive WT1 (P < .001), ZEB2 (P < .001), TWIST1 (P = .009), and FAP (P = .003). Our data suggest that CK+/VIM+ tumor cells exist, albeit in low numbers and could represent a subgroup of tumor buds in partial EMT. CK+/VIM+ stroma may be of mesothelial origin and shows features of mesenchymal cells and cancer-associated fibroblasts. These results, together with the association with metastasis point to cells in mesothelial-mesenchymal transition (MMT). This atypical stroma may be a potential target for therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer-associated stroma; Colorectal cancer; Epithelial-mesenchymal transition; Mesothelial-mesenchymal transition; Tumor budding

Mesh:

Substances:

Year:  2019        PMID: 30794893     DOI: 10.1016/j.humpath.2019.02.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

Review 1.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

2.  Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.

Authors:  Sara Imboden; Inti Zlobec; Tilman T Rau; Eva Bettschen; Carol Büchi; Lucine Christe; Amanda Rohner; Michael D Müller; Joseph W Carlson
Journal:  Mod Pathol       Date:  2020-07-29       Impact factor: 7.842

Review 3.  Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.

Authors:  Riley D Z Mullins; Ananya Pal; Thomas F Barrett; Molly E Heft Neal; Sidharth V Puram
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

4.  E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

Authors:  Jarle Bruun; Peter W Eide; Christian Holst Bergsland; Oscar Bruck; Aud Svindland; Mariliina Arjama; Katja Välimäki; Merete Bjørnslett; Marianne G Guren; Olli Kallioniemi; Arild Nesbakken; Ragnhild A Lothe; Teijo Pellinen
Journal:  Mol Oncol       Date:  2021-12-26       Impact factor: 7.449

5.  A Novel Approach for Quantifying Cancer Cells Showing Hybrid Epithelial/Mesenchymal States in Large Series of Tissue Samples: Towards a New Prognostic Marker.

Authors:  Louis Godin; Cédric Balsat; Yves-Rémi Van Eycke; Justine Allard; Claire Royer; Myriam Remmelink; Ievgenia Pastushenko; Nicky D'Haene; Cédric Blanpain; Isabelle Salmon; Sandrine Rorive; Christine Decaestecker
Journal:  Cancers (Basel)       Date:  2020-04-08       Impact factor: 6.639

Review 6.  Tumour budding and its clinical implications in gastrointestinal cancers.

Authors:  Inti Zlobec; Martin D Berger; Alessandro Lugli
Journal:  Br J Cancer       Date:  2020-06-30       Impact factor: 7.640

7.  The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.

Authors:  Cheng-Chan Yu; Sung-Ying Huang; Shu-Fang Chang; Kuan-Fu Liao; Sheng-Chun Chiu
Journal:  Molecules       Date:  2020-05-25       Impact factor: 4.411

Review 8.  Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression.

Authors:  Dona Sinha; Priyanka Saha; Anurima Samanta; Anupam Bishayee
Journal:  Biomolecules       Date:  2020-11-16

Review 9.  The epithelial-mesenchymal transition and the cytoskeleton in bioengineered systems.

Authors:  Susan E Leggett; Alex M Hruska; Ming Guo; Ian Y Wong
Journal:  Cell Commun Signal       Date:  2021-03-10       Impact factor: 7.525

10.  Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival.

Authors:  Panagiotis J Vlachostergios; Athanasios Karathanasis; Vassilios Tzortzis
Journal:  Genes (Basel)       Date:  2022-01-13       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.